Download MendeleyDiscovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.
Swain, N.A., Batchelor, D., Beaudoin, S., Bechle, B.M., Bradley, P.A., Brown, A.D., Brown, B., Butcher, K.J., Butt, R.P., Chapman, M.L., Denton, S., Ellis, D., Galan, S.R.G., Gaulier, S.M., Greener, B.S., de Groot, M.J., Glossop, M.S., Gurrell, I.K., Hannam, J., Johnson, M.S., Lin, Z., Markworth, C.J., Marron, B.E., Millan, D.S., Nakagawa, S., Pike, A., Printzenhoff, D., Rawson, D.J., Ransley, S.J., Reister, S.M., Sasaki, K., Storer, R.I., Stupple, P.A., West, C.W.(2017) J Med Chem 60: 7029-7042
- PubMed: 28682065
- DOI: https://doi.org/10.1021/acs.jmedchem.7b00598
- Primary Citation of Related Structures:
5K7K - PubMed Abstract:
A series of acidic diaryl ether heterocyclic sulfonamides that are potent and subtype selective Na V 1.7 inhibitors is described. Optimization of early lead matter focused on removal of structural alerts, improving metabolic stability and reducing cytochrome P450 inhibition driven drug-drug interaction concerns to deliver the desired balance of preclinical in vitro properties. Concerns over nonmetabolic routes of clearance, variable clearance in preclinical species, and subsequent low confidence human pharmacokinetic predictions led to the decision to conduct a human microdose study to determine clinical pharmacokinetics. The design strategies and results from preclinical PK and clinical human microdose PK data are described leading to the discovery of the first subtype selective Na V 1.7 inhibitor clinical candidate PF-05089771 (34) which binds to a site in the voltage sensing domain.
Organizational Affiliation:
Icagen Inc. , 4222 Emperor Blvd no. 350, Durham, North Carolina 27703, United States.
